Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States
The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.
Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors
Stavudine (Zerit, d4T)
Last Updated: December 7, 2018; Last Reviewed: December 7, 2018
Excerpt from Table 10
|Formulation||Dosing Recommendationsa||Use in Pregnancy|
Note: Generic products are available for all formulations.
|Standard Adult Dosese
Body Weight ≥60 kg:
Dosing in Pregnancy:
|d4T is not recommended for pregnant women
High placental transfer.b
No evidence of human teratogenicity (can rule out 2-fold increase in overall birth defects).
Lactic acidosis, sometimes fatal, has been reported in pregnant women receiving ddI and d4T together.
a Individual ARV drug dosages may need to be adjusted in renal or hepatic insufficiency (for details, see the Adult and Adolescent Guidelines Appendix B, Table 8).
b Placental transfer categories—Mean or median cord blood/maternal delivery plasma drug ratio:
e WHO recommends maximum dose of 30 mg regardless of weight.
Key to Acronyms: ARV = antiretroviral; d4T = stavudine; ddI = didanosine; PK = pharmacokinetic; WHO = World Health Organization
- AIDSinfo Drug Database
- AIDSinfo Patient Materials: Preventing Mother-to-Child Transmission of HIV
- AIDSinfo Patient Materials: HIV Medicines During Pregnancy and Childbirth
- AIDSinfo Patient Materials: Protecting Baby from HIV
- AETC National HIV Curriculum
- How to Cite These Guidelines
- Perinatal Guidelines Archive